Literature DB >> 6352815

A rapid and sensitive assay for neuraminidase using peanut lectin hemagglutination: application to Vibrio cholera and Trypanosoma cruzi.

M E Pereira.   

Abstract

A neuraminidase assay based on peanut lectin agglutination is described. Human red blood cells are used both as substrate for the enzyme and as probe for the lectin. The validity of the method is ascertained by measuring the enzyme and lectin activities on erythrocytes whose outer membrane sialic acid was labeled with tritium after oxidation with sodium periodate followed by reduction with sodium borotritiide. The neuraminidases of Trypanosoma cruzi and Vibrio cholera are used as examples; in both cases, a linear relationship is observed between the degree of erythrocyte desialylation and the peanut hemagglutination titer. For the hemagglutination assay, lectin in homogeneous form as well as in crude peanut extracts may be used, and free sialic acid need not be separated from substrate-bound sialic acid. The hemagglutinating activity of peanut lectin is not affected by pre-treatment of the erythrocytes with various proteases. The method is particularly useful in the neuraminidase analysis of multiple samples, such as in gel filtration chromatography and for screening of hybridoma antibodies against neuraminidase.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6352815     DOI: 10.1016/0022-1759(83)90206-5

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  12 in total

1.  Mobilization of sialidase from intracellular stores to the surface of human neutrophils and its role in stimulated adhesion responses of these cells.

Authors:  A S Cross; D G Wright
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

2.  A neuraminidase from Trypanosoma cruzi removes sialic acid from the surface of mammalian myocardial and endothelial cells.

Authors:  P Libby; J Alroy; M E Pereira
Journal:  J Clin Invest       Date:  1986-01       Impact factor: 14.808

3.  Immunocytochemical localization of neuraminidase in Trypanosoma cruzi.

Authors:  T Souto-Padrón; G Harth; W de Souza
Journal:  Infect Immun       Date:  1990-03       Impact factor: 3.441

4.  Specific inhibition of Trypanosoma cruzi neuraminidase by the human plasma glycoprotein "cruzin".

Authors:  R P Prioli; I Rosenberg; M E Pereira
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

5.  Identification of a developmentally regulated sialidase in Eimeria tenella that is immunologically related to the Trypanosoma cruzi enzyme.

Authors:  J L Pellegrin; E Ortega-Barria; R P Prioli; M Buerger; R G Strout; J Alroy; M E Pereira
Journal:  Glycoconj J       Date:  1993-02       Impact factor: 2.916

6.  A novel immunoprecipitation strategy identifies a unique functional mimic of the glial cell line-derived neurotrophic factor family ligands in the pathogen Trypanosoma cruzi.

Authors:  Bo Lu; Mercio PereiraPerrin
Journal:  Infect Immun       Date:  2008-06-09       Impact factor: 3.441

7.  A membrane-associated neuraminidase in Entamoeba histolytica trophozoites.

Authors:  I A Udezulu; G J Leitch
Journal:  Infect Immun       Date:  1987-01       Impact factor: 3.441

8.  Phospholipase C-mediated release of neuraminidase from Tritrichomonas foetus cell surface.

Authors:  B P Dias Filho; W De Souza; A F Andrade; M J Esteves; J Angluster
Journal:  Parasitol Res       Date:  1995       Impact factor: 2.289

9.  Sera from chronic Chagasic patients and rodents infected with Trypanosoma cruzi inhibit trans-sialidase by recognizing its amino-terminal and catalytic domain.

Authors:  V L Pereira-Chioccola; S Schenkman; J K Kloetzel
Journal:  Infect Immun       Date:  1994-07       Impact factor: 3.441

10.  Antipneumococcal activity of neuraminidase inhibiting artocarpin.

Authors:  E Walther; M Richter; Z Xu; C Kramer; S von Grafenstein; J Kirchmair; U Grienke; J M Rollinger; K R Liedl; H Slevogt; A Sauerbrei; H P Saluz; W Pfister; M Schmidtke
Journal:  Int J Med Microbiol       Date:  2014-12-18       Impact factor: 3.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.